Ubs Asset Management Americas Inc Kal Vista Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $446 Billion
- Q3 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 13,600 shares of KALV stock, worth $181,152. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,600Holding current value
$181,152% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding KALV
# of Institutions
156Shares Held
59.9MCall Options Held
1.21MPut Options Held
865K-
Vr Adviser, LLC New York, NY6.73MShares$89.6 Million12.35% of portfolio
-
Tang Capital Management LLC San Diego, CA5.04MShares$67.2 Million2.77% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.04MShares$67.1 Million2.57% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.77MShares$63.5 Million1.73% of portfolio
-
Capital World Investors Los Angeles, CA3.18MShares$42.3 Million0.01% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $328M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...